54109-16-9

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(TRIFLUOROMETHYL)PHENACYL BROMIDE is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its reactivity with other molecules allows for the creation of new drugs with potential therapeutic applications.
Used in Sulfonyl Urea Synthesis:
In the synthesis of sulfonyl ureas, 2-(TRIFLUOROMETHYL)PHENACYL BROMIDE is used as a reactant in the condensation reaction with benzenesulfinic acid ammonium salt. This reaction leads to the formation of β-keto sulfone, which is an important step in the production of sulfonyl ureas.
Used in Rap-Stoermer Condensation Reaction:
2-(TRIFLUOROMETHYL)PHENACYL BROMIDE is also utilized in the Rap-Stoermer condensation reaction, where it reacts with other compounds to form complex molecular structures with potential applications in the pharmaceutical industry.

InChI:InChI=1/C9H6BrF3O/c10-5-8(14)6-3-1-2-4-7(6)9(11,12)13/h1-4H,5H2

Upstream product

• 17408-14-9 1-(2-(trifluoromethyl)phenyl)ethan-1-one 
• 262268-69-9 1-(2-bromoethynyl)-2-(trifluoromethyl)benzene 

Downstream Products

• 129486-38-0 4-(2-trifluoromethylphenyl)-2-<<4(5)-methyl-5(4)-imidazolyl>methyl>thiazole 
• 42755-97-5 [2-Oxo-2-(2-trifluoromethyl-phenyl)-ethyl]-phosphonic acid diethyl ester 
• 254911-94-9 methyl 4-[4-(2-trifluoromethylphenyl)-2-oxazolyl]benzoate 
• 145933-93-3 2,3-Dimethyl-7(2-trifluoromethylphenacyl)-pyrrolo[2,3-b]pyridine hydrobromide 
• 881673-53-6 ethyl 2-cyano-4-oxo-4-[2-(trifluoromethyl)phenyl]butanoate 
• 1207477-02-8 C₃₃H₂₄F₃N₃O₃ 
• 881673-68-3 ethyl 2-chloro-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate 
• 881673-54-7 ethyl 5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate 
• 1566229-29-5 2-hydroxy-2'-trifluoromethylacetophenone 

Relevant academic research and scientific papers

Nucleus-independent chemical shift (NICS) as a criterion for the design of new antifungal benzofuranones

The assertion made by Wu et al. that aromaticity may have considerable implications for molecular design motivated us to use nucleus-independent chemical shifts (NICS) as an aromaticity criterion to evaluate the antifungal activity of two series of indol-4-ones. A linear regression analysis of NICS and antifungal activity showed that both tested variables were significantly related (p –1 for Candida glabrata, Candida krusei and Candida guilliermondii with compounds 15-32, 15-15 and 15-1. The MIC for filamentous fungi was 1.95 μg·mL–1 for Aspergillus niger for compounds 15-1, 15-33 and 15-34. The results obtained support the use of NICS in the molecular design of compounds with antifungal activity.

NON-IONIC LOW DIFFUSING PHOTO-ACID GENERATORS

Non-ionic photo-acid generating (PAG) compounds were prepared that contain an aryl ketone group. The disclosed non-polymeric PAGs release a strong sulfonic acid when exposed to high energy radiation such as deep UV or extreme UV light. The photo-generated sulfonic acid has a low diffusion rate in an exposed resist layer subjected to a post-exposure bake (PEB) at 100° C. to 150° C., resulting in formation of good line patterns after development. At higher temperatures, the PAGs undergo a thermal reaction to form a sulfonic acid.

Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action

With the aim to find a novel long-lasting potassium-competitive acid blocker (P-CAB) that would perfectly overcome the limitations of proton pump inhibitors (PPIs), we tried various approaches based on pyrrole derivative 1b as a lead compound. As part of

Proton pump inhibitors

A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R 1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R 2 , R 3 and R 4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R 5 and R 6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof. or a prodrug thereof is provided.

AgF/TFA-promoted highly efficient synthesis of α-haloketones from haloalkynes

A AgF/TFA-promoted highly efficient synthesis of a wide range of α-haloketones from haloalkynes is described. The reactions are conducted under convenient conditions and provide products in moderate to excellent yields, with broad substrate scope, including a variety of aromatic chloroalkynes and bromoalkynes.

Diarylthiazole: An antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system

Diarylthiazole (DAT), a hit from diversity screening, was found to have potent antimycobacterial activity against Mycobacterium tuberculosis (Mtb). In a systematic medicinal chemistry exploration, we demonstrated chemical opportunities to optimize the potency and physicochemical properties. The effort led to more than 10 compounds with submicromolar MICs and desirable physicochemical properties. The potent antimycobacterial activity, in conjunction with low molecular weight, made the series an attractive lead (antibacterial ligand efficiency (ALE) >0.4). The series exhibited excellent bactericidal activity and was active against drug-sensitive and resistant Mtb. Mutational analysis showed that mutations in prrB impart resistance to DAT compounds but not to reference drugs tested. The sensor kinase PrrB belongs to the PrrBA two component system and is potentially the target for DAT. PrrBA is a conserved, essential regulatory mechanism in Mtb and has been shown to have a role in virulence and metabolic adaptation to stress. Hence, DATs provide an opportunity to understand a completely new target system for antimycobacterial drug discovery.

Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography

Inhibition of the tyrosine kinase erythropoietin-producing human hepatocellular carcinoma receptor B4 (EphB4) is an effective strategy for the treatment of solid tumors. We have previously reported a low nanomolar ATP-competitive inhibitor of EphB4 discovered in silico by fragment-based high-throughput docking combined with explicit solvent molecular dynamics simulations. Here we present a second generation of EphB4 inhibitors that show high inhibitory potency in both enzymatic and cell-based assays while preserving the appealing selectivity profile exhibited by the parent compound. In addition, respectable levels of antiproliferative activity for these compounds have been obtained. Finally, the binding mode predicted by docking and molecular dynamics simulations is validated by solving the crystal structures of three members of this chemical class in complex with the EphA3 tyrosine kinase whose ATP-binding site is essentially identical to that of EphB4.

SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin- modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of d

NOVEL COMPOUNDS

Disclosed are retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

Thiazolyl-Benzimidazoles

The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.